Connection

David Taber to Immunosuppressive Agents

Back to Details
This is a "connection" page, showing publications David Taber has written about Immunosuppressive Agents.
David Taber
Connection Strength
11.609
Immunosuppressive Agents
  1. A viewpoint describing the American Society of Transplantation rationale to conduct a comprehensive patient survey assessing unmet immunosuppressive therapy needs. Clin Transplant. 2023 03; 37(3):e14876.
    View in: PubMed
    Score: 0.625
  2. Etiologies and Outcomes Associated With Tacrolimus Levels Out of a Typical Range That Lead to High Variability in Kidney Transplant Recipients. Ther Drug Monit. 2021 06 01; 43(3):401-407.
    View in: PubMed
    Score: 0.562
  3. Immunosuppression trends in solid organ transplantation: The future of individualization, monitoring, and management. Pharmacotherapy. 2021 01; 41(1):119-131.
    View in: PubMed
    Score: 0.546
  4. Exploratory Analysis of the Impact of an mHealth Medication Adherence Intervention on Tacrolimus Trough Concentration Variability: Post Hoc Results of a Randomized Controlled Trial. Ann Pharmacother. 2020 12; 54(12):1185-1193.
    View in: PubMed
    Score: 0.525
  5. Dosing Requirements of Extended-Release Tacrolimus (Astagraf XL) in African American Kidney Transplant Recipients Converted from Immediate-Release Tacrolimus (AAAKTRS). Ther Drug Monit. 2020 06; 42(3):415-420.
    View in: PubMed
    Score: 0.525
  6. Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients. Clin Transplant. 2019 10; 33(10):e13679.
    View in: PubMed
    Score: 0.499
  7. Change in Mycophenolate and Tacrolimus Exposure by Transplant Vintage and Race. Exp Clin Transplant. 2019 12; 17(6):707-713.
    View in: PubMed
    Score: 0.475
  8. It is time for board certification in transplant pharmacotherapy. Am J Transplant. 2018 09; 18(9):2370-2371.
    View in: PubMed
    Score: 0.459
  9. Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. Transplantation. 2017 12; 101(12):2931-2938.
    View in: PubMed
    Score: 0.441
  10. Cytolytic Induction Therapy Improves Clinical Outcomes in African-American Kidney Transplant Recipients. Ann Surg. 2017 09; 266(3):450-456.
    View in: PubMed
    Score: 0.434
  11. Improvement in immunosuppression therapy monitoring in organ transplant recipients. Am J Health Syst Pharm. 2017 Sep 01; 74(17 Supplement 3):S67-S74.
    View in: PubMed
    Score: 0.434
  12. Ambulatory Care Coordination Issues With Dual Use Veteran Organ Transplant Recipients. Prog Transplant. 2017 06; 27(2):187-191.
    View in: PubMed
    Score: 0.421
  13. The Impact of Health Care Appointment Non-Adherence on Graft Outcomes in Kidney Transplantation. Am J Nephrol. 2017; 45(1):91-98.
    View in: PubMed
    Score: 0.412
  14. African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipients. Pharmacotherapy. 2015 Jun; 35(6):569-77.
    View in: PubMed
    Score: 0.370
  15. Prediction of medication non-adherence and associated outcomes in pediatric kidney transplant recipients. Pediatr Transplant. 2015 Aug; 19(5):555-62.
    View in: PubMed
    Score: 0.369
  16. Induction therapy: clinical and quality of life outcomes in aged renal transplant recipients. Clin Transplant. 2015 Mar; 29(3):222-6.
    View in: PubMed
    Score: 0.362
  17. Clinical and economic outcomes associated with medication errors in kidney transplantation. Clin J Am Soc Nephrol. 2014 May; 9(5):960-6.
    View in: PubMed
    Score: 0.344
  18. Racial comparisons of everolimus pharmacokinetics and pharmacodynamics in adult kidney transplant recipients. Ther Drug Monit. 2013 Dec; 35(6):753-9.
    View in: PubMed
    Score: 0.334
  19. Disruptions in the supply of medications used in transplantation: implications and management strategies for the transplant clinician. Am J Transplant. 2013 Jan; 13(1):20-30.
    View in: PubMed
    Score: 0.310
  20. Long-term efficacy of induction therapy with anti-interleukin-2 receptor antibodies or thymoglobulin compared with no induction therapy in renal transplantation. Transplant Proc. 2008 Dec; 40(10):3401-7.
    View in: PubMed
    Score: 0.236
  21. Use of bone health protocol to identify and prevent bone disease in kidney and pancreas transplant recipients. Ann Pharmacother. 2007 Jun; 41(6):944-50.
    View in: PubMed
    Score: 0.212
  22. Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients. Liver Transpl. 2002 Mar; 8(3):219-23.
    View in: PubMed
    Score: 0.148
  23. Impact of a pharmacist-led, mHealth-based intervention on tacrolimus trough variability in kidney transplant recipients: A report from the TRANSAFE Rx randomized controlled trial. Am J Health Syst Pharm. 2021 07 09; 78(14):1287-1293.
    View in: PubMed
    Score: 0.142
  24. Safety and Efficacy of Perioperative Sublingual Tacrolimus in Pancreas Transplant Compared With Oral Tacrolimus. Exp Clin Transplant. 2021 06; 19(6):592-595.
    View in: PubMed
    Score: 0.140
  25. Clinical Outcomes of Older Kidney Transplant Recipients. Am J Med Sci. 2021 08; 362(2):130-134.
    View in: PubMed
    Score: 0.138
  26. A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation. Am J Transplant. 2020 08; 20(8):1969-1983.
    View in: PubMed
    Score: 0.132
  27. Drug-drug interaction between chloramphenicol and tacrolimus in a liver transplant recipient. Transplant Proc. 2000 May; 32(3):660-2.
    View in: PubMed
    Score: 0.130
  28. Preliminary assessment of safety and adherence to a once-daily immunosuppression regimen in kidney transplantation: Results of a randomized controlled pilot study. Clin Transplant. 2020 04; 34(4):e13844.
    View in: PubMed
    Score: 0.129
  29. Using informatics and mobile health to improve medication safety monitoring in kidney transplant recipients. Am J Health Syst Pharm. 2019 Jul 18; 76(15):1143-1149.
    View in: PubMed
    Score: 0.123
  30. The impact of time-varying clinical surrogates on disparities in African-American kidney transplant recipients - a retrospective longitudinal cohort study. Transpl Int. 2019 01; 32(1):84-94.
    View in: PubMed
    Score: 0.117
  31. Belatacept in Solid Organ Transplant: Review of Current Literature Across Transplant Types. Transplantation. 2018 09; 102(9):1440-1452.
    View in: PubMed
    Score: 0.116
  32. A Comparative Effectiveness Analysis of Early Steroid Withdrawal in Black Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2017 01 06; 12(1):131-139.
    View in: PubMed
    Score: 0.103
  33. Quantifying the Race Stratified Impact of Socioeconomics on Graft Outcomes in Kidney Transplant Recipients. Transplantation. 2016 07; 100(7):1550-7.
    View in: PubMed
    Score: 0.100
  34. Kidney transplant recipients' attitudes about using mobile health technology for managing and monitoring medication therapy. J Am Pharm Assoc (2003). 2016 Jul-Aug; 56(4):450-454.e1.
    View in: PubMed
    Score: 0.100
  35. Inclusion of dynamic clinical data improves the predictive performance of a 30-day readmission risk model in kidney transplantation. Transplantation. 2015 Feb; 99(2):324-30.
    View in: PubMed
    Score: 0.091
  36. Significant racial differences in the key factors associated with early graft loss in kidney transplant recipients. Am J Nephrol. 2014; 40(1):19-28.
    View in: PubMed
    Score: 0.087
  37. Clinical and economic analysis of delayed administration of antithymocyte globulin for induction therapy in kidney transplantation. Prog Transplant. 2013 Mar; 23(1):33-8.
    View in: PubMed
    Score: 0.079
  38. Improved patient safety and outcomes with a comprehensive interdisciplinary improvement initiative in kidney transplant recipients. Am J Med Qual. 2013 Mar-Apr; 28(2):103-12.
    View in: PubMed
    Score: 0.076
  39. The impact of early corticosteroid withdrawal on graft survival in liver transplant recipients. Transplant Proc. 2012 Jun; 44(5):1323-8.
    View in: PubMed
    Score: 0.075
  40. Generic immunosuppression: deciphering the message our patients are receiving. Ann Pharmacother. 2012 May; 46(5):671-7.
    View in: PubMed
    Score: 0.075
  41. A critical analysis of racial difference with mycophenolate mofetil (MMF) dosing, clinical outcomes and adverse effects in pediatric kidney transplant patients. Clin Transplant. 2011 Jul-Aug; 25(4):534-40.
    View in: PubMed
    Score: 0.066
  42. Efficacy of induction therapy on acute rejection and graft outcomes in African American kidney transplantation. Clin Transplant. 2010 Jan-Feb; 24(1):40-7.
    View in: PubMed
    Score: 0.060
  43. Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? Transplantation. 2005 Dec 15; 80(11):1633-5.
    View in: PubMed
    Score: 0.048
  44. Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemother Pharmacol. 2005 Oct; 56(4):421-6.
    View in: PubMed
    Score: 0.046
  45. Long-term outcome of sirolimus rescue in kidney-pancreas transplantation. Transplantation. 2004 Aug 27; 78(4):619-22.
    View in: PubMed
    Score: 0.044
  46. Long-term outcome of sirolimus rescue in kidney-pancreas transplantation. Transplant Proc. 2004 May; 36(4):1058-60.
    View in: PubMed
    Score: 0.043
  47. Phenotype of immunosuppression reduction after kidney transplantation. Clin Transplant. 2020 10; 34(10):e14047.
    View in: PubMed
    Score: 0.033
  48. Protocol-based nurse coordinator management of ambulatory tacrolimus dosing in de novo renal transplant recipients-A single-center experience with a large African American population. Clin Transplant. 2019 10; 33(10):e13701.
    View in: PubMed
    Score: 0.031
  49. Transplanting Sensitized Kidney Transplant Patients With Equivalent Outcomes Utilizing Stringent HLA Crossmatching. Exp Clin Transplant. 2017 Feb; 15(1):47-55.
    View in: PubMed
    Score: 0.025
  50. A randomized, prospective comparison of transition to sirolimus-based CNI-minimization or withdrawal in African American kidney transplant recipients. Clin Transplant. 2016 05; 30(5):528-33.
    View in: PubMed
    Score: 0.024
  51. Incidence, risk factors, and outcomes of opportunistic infections in pediatric renal transplant recipients. Pediatr Transplant. 2016 Feb; 20(1):44-8.
    View in: PubMed
    Score: 0.024
  52. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation. Ann Surg. 2014 May; 259(5):888-93.
    View in: PubMed
    Score: 0.022
  53. Hypertension after kidney transplantation: a pathophysiologic approach. Curr Hypertens Rep. 2013 Oct; 15(5):458-69.
    View in: PubMed
    Score: 0.021
  54. Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation. Transpl Infect Dis. 2013 Dec; 15(6):551-8.
    View in: PubMed
    Score: 0.021
  55. Early aspirin therapy may reduce hepatic artery thrombosis in liver transplantation. Transplant Proc. 2013 Jan-Feb; 45(1):330-4.
    View in: PubMed
    Score: 0.019
  56. Graft outcomes in pediatric kidney transplantation: focus on the role of race. Saudi J Kidney Dis Transpl. 2012 Jul; 23(4):684-92.
    View in: PubMed
    Score: 0.019
  57. Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection. Clin J Am Soc Nephrol. 2012 Jun; 7(6):1003-9.
    View in: PubMed
    Score: 0.019
  58. Can preemptive cytomegalovirus monitoring be as effective as universal prophylaxis when implemented as the standard of care in patients at moderate risk? Transplantation. 2010 May 27; 89(10):1218-23.
    View in: PubMed
    Score: 0.016
  59. Potential differences in kidney allograft outcomes between ethnicities when converting to sirolimus base immunosuppression. Transplant Proc. 2009 Dec; 41(10):4131-7.
    View in: PubMed
    Score: 0.016
  60. Comparison of efficacy of induction therapy in low immunologic risk African-American kidney transplant recipients. Transpl Int. 2010 May 01; 23(5):500-5.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.